Qualifying Therapeutic Discovery Project Credits for the State of New Jersey
The listings below represent the applicants that are eligible for a Qualifying Therapeutic Discovery Program Credit.
The project descriptions below were extracted from the applicant certification forms as submitted. The list provides only the applicant name and amount of the credit for each project for which the disclosure of additional information was not authorized.
|Applicant Name||Project Name||Eligible Credit Amount 2009||Eligible Credit Amount 2010|
|GENMAB INC||Zanolimumab("HuMax-CD4) Treatment for a form of Cancer, Cutaneous T-cell Lymphoma||$ 244,479.25|
|Orthogen LLC||$ 121,000.00|